Characteristic | All (N = 143) | On ART with viral suppression (n = 111) | On ART, suppressed without HCV (n = 71) |
---|---|---|---|
Age (years, median (IQR) | 45 (39–48) | 44.0 (38.9–49.1) | 42.8 (36.7–49.0) |
Gender n (%) | |||
Female | 52 (36.4%) | 39 (35.1%) | 27 (38.0%) |
Male | 91 (63.6%) | 72 (64.9%) | 44 (62.0%) |
Ethnicity n (%) | |||
Caucasian | 94 (65.7%) | 76 (68.5%) | 36 (50.7%) |
African | 40 (28%) | 31 (27.9%) | 31 (43.7%) |
Other | 9 (6.3%) | 4 (3.6%) | 4 (5.6%) |
HIV-transmission risk group n (%) | |||
Heterosexual | 52 (36.4%) | 43 (38.8%) | 41 (57.8%) |
IDU | 47 (32.9%) | 38 (34.2%) | 4 (5.6%) |
MSM | 35 (24.4%) | 27 (24.3%) | 24 (33.8%) |
Needle stick/unknown | 9 (6.3%) | 3 (2.7%) | 2 (2.8%) |
Hepatitis C Ab: positive n (%) | 50 (35.0%) | 40 (36.0%) | |
Hepatitis B sAg: positive n (%) | 4 (2.8%) | 4 (3.6%) | |
Time since ART initiation (years, median (IQR)) | 7.5 (3.7–10.4) | 7.8 (4.4–10.8) | 8.6 (4.9–10.7) |
HIV-RNA (copies/ml) n (%) | |||
≤ 40 | 113 (79%) | ||
ART exposure n (%) | |||
Experienced | 129 (90.2%) | ||
ART regimes n (%) | |||
PI-based ART | 72 (55.8%) | 59 (53.2%) | |
NNRTI based ART | 52 (40.3%) | 47 (42.3%) | |
INSTI based ART | 5 (3.9%) | 5 (4.5%) | |
rs12979860 n (%) | |||
C/C | 46 (32.2%) | 39 (35.1%) | 22 (31.0%) |
C/T | 73 (51.0%) | 57 (51.4%) | 38 (53.5%) |
T/T | 24 (16.8%) | 15 (13.5%) | 11 (15.5%) |
rs368234815 n (%) | |||
T/T | 61 (42.6%) | 48 (43.2%) | 28 (39.5%) |
T/ΔG | 53 (37.1%) | 43 (38.8%) | 26 (36.6%) |
ΔG/ΔG | 29 (20.3%) | 20 (18.0%) | 17 (23.9%) |